Graft-versus-host disease-associated angiomatosis: A clinicopathologically distinct entity - 17/09/14
, Rena C. Zuo, BA c, Alejandro Gru, MD a, b, Alisha N. Plotner, MD a, Sarah A. Sweeney, MD d, Steven M. Devine, MD e, Sharon R. Hymes, MD d, Edward W. Cowen, MD, MHSc cAbstract |
Background |
Chronic graft-versus-host disease (GVHD) may present with various cutaneous manifestations. Isolated case reports describe eruptive angiomas in this setting.
Objective |
We sought to provide a clinical and pathologic description of vascular proliferations in patients with GVHD.
Methods |
Cases of documented GVHD associated with vascular proliferations were collected from the National Institutes of Health, Ohio State University, and MD Anderson Cancer Center.
Results |
Eleven patients with a diagnosis of GVHD who developed vascular proliferations were identified. All patients manifested sclerotic type chronic GVHD of the skin. Vascular lesions were first documented a median of 44 months after transplantation and occurred primarily on the lower extremities or trunk. Histopathology revealed anastomosing networks of thin-walled vascular proliferations in a vague lobular growth pattern, with overlying epidermal acanthosis, peripheral collarette, ulceration, and disorganized fibroblast-rich and fibrotic stroma. Improvement was noted in 1 patient treated with propranolol and sirolimus and 1 patient with electrocautery.
Limitations |
Given the retrospective nature of the study, the overall incidence of vascular lesions in patients with GVHD is unknown. Histopathology was present for review on only 3 of 11 patients.
Conclusion |
The phenomenon of vascular lesions appears to be relatively specific for sclerotic type chronic GVHD when compared with other fibrosing diseases. We propose the term “graft-versus-host disease–associated angiomatosis” to describe this entity.
Le texte complet de cet article est disponible en PDF.Key words : angioendotheliomatosis, angiomatosis, eruptive angiomas, graft-versus-host disease, sclerosis, sclerotic, vascular tumors
Abbreviations used : AA, aGVHD, AVL, cGVHD, GVHD, HSCT
Plan
| Supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute and the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from Pfizer Inc, the Doris Duke Charitable Foundation, the Alexandria Real Estate Equities Inc and Mr and Mrs Joel S. Marcus, and the Howard Hughes Medical Institute, as well as other private donors. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 4
P. 745-753 - octobre 2014 Retour au numéro
Article précédent
- Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients
- Babak Monshi, Christian Posch, Igor Vujic, Alma Sesti, Silke Sobotka, Klemens Rappersberger
- Managing skin toxicities related to panitumumab
- Hagit Bergman, Tara Walton, Ryan Del Bel, Jack T. Seki, Ava Rafii, Wei Xu, Gideon Koren, Neil Shear, Monika K. Krzyzanowska, Doris Howell, Geoffrey Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?